Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab

Currently, eculizumab is the main effective treatment for paroxysmal nocturnal hemoglobinuria (PNH). The aim of this randomized multicenter noninferiority study was to evaluate the efficacy and safety of the Biosimilar (Elizaria) in comparison with the Originator (Soliris) in patients with PNH. Bios...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulagin, Alexander D., Ptushkin, Vadim V., Lukina, Elena A., Davydkin, Igor L., Korobkin, Alexander V., Shamrai, Vladimir S., Konstantinova, Tatyana S., Kaporskaya, Tatyana S., Mitina, Tatyana A., Ksenzova, Tatyana I., Zuev, Evgeny V., Markova, Oksana A., Gapchenko, Elena V., Kudlay, Dmitry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510904/
https://www.ncbi.nlm.nih.gov/pubmed/34398258
http://dx.doi.org/10.1007/s00277-021-04624-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510904/
https://www.ncbi.nlm.nih.gov/pubmed/34398258
http://dx.doi.org/10.1007/s00277-021-04624-7

Ejemplares similares